{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:12:13Z","timestamp":1791807133043,"version":"4.3.4"},"reference-count":64,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anticancer Therapy"],"published-print":{"date-parts":[[2025,6,3]]},"DOI":"10.1080\/14737140.2025.2501744","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T17:08:01Z","timestamp":1746637681000},"page":"599-608","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["Implementation of a CAR-T cell therapy program in India"],"prefix":"10.1080","volume":"25","author":[{"given":"Hema","family":"Hotchandani","sequence":"first","affiliation":[{"name":"Tata Memorial Hospital","place":["Mumbai, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manju","family":"Sengar","sequence":"additional","affiliation":[{"name":"Tata Memorial Hospital","place":["Mumbai, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alok","family":"Shetty","sequence":"additional","affiliation":[{"name":"Tata Memorial Hospital","place":["Mumbai, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupa","family":"John","sequence":"additional","affiliation":[{"name":"Tata Memorial Hospital","place":["Mumbai, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atharva","family":"Karulkar","sequence":"additional","affiliation":[{"name":"ImmunoAdoptive Cell Therapy Private Limited (ImmunoACT Pvt Ltd)","place":["Mumbai, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devanshi","family":"Kalra","sequence":"additional","affiliation":[{"name":"ImmunoAdoptive Cell Therapy Private Limited (ImmunoACT Pvt Ltd)","place":["Mumbai, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smrithi","family":"Ravikumar","sequence":"additional","affiliation":[{"name":"ImmunoAdoptive Cell Therapy Private Limited (ImmunoACT Pvt Ltd)","place":["Mumbai, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Jaiswal","sequence":"additional","affiliation":[{"name":"ImmunoAdoptive Cell Therapy Private Limited (ImmunoACT Pvt Ltd)","place":["Mumbai, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuktam","family":"Yadav","sequence":"additional","affiliation":[{"name":"ImmunoAdoptive Cell Therapy Private Limited (ImmunoACT Pvt Ltd)","place":["Mumbai, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sugandha","family":"Parkar","sequence":"additional","affiliation":[{"name":"Tata Memorial Hospital","place":["Mumbai, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuradha","family":"Walawalkar","sequence":"additional","affiliation":[{"name":"Tata Memorial Hospital","place":["Mumbai, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali","family":"Kadam","sequence":"additional","affiliation":[{"name":"Tata Memorial Hospital","place":["Mumbai, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhausaheb","family":"Bagal","sequence":"additional","affiliation":[{"name":"Tata Memorial Hospital","place":["Mumbai, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingaraj","family":"Nayak","sequence":"additional","affiliation":[{"name":"Tata Memorial Hospital","place":["Mumbai, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Purwar","sequence":"additional","affiliation":[{"name":"ImmunoAdoptive Cell Therapy Private Limited (ImmunoACT Pvt Ltd)","place":["Mumbai, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasmukh","family":"Jain","sequence":"additional","affiliation":[{"name":"Tata Memorial Hospital","place":["Mumbai, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"key":"e_1_3_4_3_1","unstructured":"Cancer Today [Internet]. Lyon (FR): International Agency for Research on Cancer; [cited 2024 Oct 11]. Available from: https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/356-india-fact-sheet.pdf"},{"key":"e_1_3_4_4_1","unstructured":"Ferlay J Ervik M Lam F et al. Global cancer observatory: cancer Today [Internet]. Lyon: International Agency for Research on Cancer; 2024 [cited 2024 Oct 11]. https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/356-india-fact-sheet.pdf"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijmr.ijmr_1821_22"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.4103\/jpgm.JPGM_391_18"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijc.IJC_656_17"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2021.100826"},{"key":"e_1_3_4_9_1","unstructured":"Tisagenlecleucel (kymriah) approved to treat some lymphomas - NCI [Internet]. Bethesda (MD): National Cancer Institute; 2018 [cited 2024 Oct 3]. Available from: https:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2018\/tisagenlecleucel-fda-lymphoma"},{"key":"e_1_3_4_10_1","unstructured":"Center for Drug Evaluation and Research. FDA approves axicabtagene ciloleucel for second-line treatment of large B-cell lymphoma [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2024 [cited 2024 Oct 3]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-axicabtagene-ciloleucel-second-line-treatment-large-b-cell-lymphoma"},{"key":"e_1_3_4_11_1","unstructured":"CAR T cells: engineering immune cells to treat cancer - NCI [Internet]. Bethesda (MD): National Cancer Institute; 2013 [cited 2024 Oct 3]. Available from: https:\/\/www.cancer.gov\/about-cancer\/treatment\/research\/car-t-cells"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1397613"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1691201"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00607-3"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018730"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116596"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01731-4"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003001"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017015164"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00375-2"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021243"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002118"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021567"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-202335"},{"key":"e_1_3_4_26_1","unstructured":"Center for Drug Evaluation and Research. FDA approves tisagenlecleucel for B-cell ALL and tocilizumab for cytokine release syndrome [internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2019 Feb 9 [cited 2024 Nov 14]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-tisagenlecleucel-b-cell-all-and-tocilizumab-cytokine-release-syndrome"},{"key":"e_1_3_4_27_1","unstructured":"Center for Drug Evaluation and Research. FDA approves brexucabtagene autoleucel for relapsed or refractory B-cell precursor acute lymphoblastic leukemia [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2024 Aug 9 [cited 2024 Nov 14]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-brexucabtagene-autoleucel-relapsed-or-refractory-b-cell-precursor-acute-lymphoblastic"},{"key":"e_1_3_4_28_1","unstructured":"Center for Drug Evaluation and Research. FDA approves obecabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2024 Nov 8 [cited 2024 Nov 14]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-obecabtagene-autoleucel-adults-relapsed-or-refractory-b-cell-precursor-acute"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-023-00593-3"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21168-6"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2020.08.007"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2023.08.007"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.02.018"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020703"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14071"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2018.10.004"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpedsurg.2024.02.022"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2022.05.003"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15178"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009019"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.46989\/001c.116261"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.335"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2023.10.001"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-185507"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.755549"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03458"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.03.006"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020578"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017415"},{"key":"e_1_3_4_50_1","unstructured":"German Lymphoma Alliance. Scores [Internet]. [cited 2024 Dec 8]. Available from: https:\/\/www.german-lymphoma-alliance.de\/Scores.html"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010543"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00077-2"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7372"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1398078"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008320"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24)01792-0"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2021.09.007"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00694-6"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02182-7"},{"key":"e_1_3_4_60_1","unstructured":"Memorial Sloan Kettering Cancer Center. Allogeneic CAR T cell therapy for multiple myeloma shows promise [internet]. New York (NY): Memorial Sloan Kettering Cancer Center; 2023 [cited 2024 Dec 8]. Available from: https:\/\/www.mskcc.org\/clinical-updates\/allogeneic-car-cell-therapy-multiple-myeloma-shows-promise"},{"key":"e_1_3_4_61_1","unstructured":"Mayo Clinic. A study to evaluate the safety and effectiveness of ALLO-501A CAR T cell therapy in adults with relapsed\/refractory large B cell lymphoma [Internet]. Rochester (MN): Mayo Clinic; [cited 2024 Dec 8]. Available from: https:\/\/www.mayo.edu\/research\/clinical-trials\/cls-20510895"},{"key":"e_1_3_4_62_1","unstructured":"Insight IIT Bombay. CAR-T: from lab to life [Internet]. 2024 [cited 2024 Nov 11]. Available from: https:\/\/insightiitb.org\/car-t-from-lab-to-life\/"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.31547\/bct-2024-008"},{"key":"e_1_3_4_64_1","unstructured":"Trading Economics. India GDP per capita [Internet]. [cited 2024 Nov 11]. Available from: https:\/\/tradingeconomics.com\/india\/gdp-per-capita"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-022-02778-6"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101082"}],"container-title":["Expert Review of Anticancer Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737140.2025.2501744","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T02:57:20Z","timestamp":1748833040000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737140.2025.2501744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":64,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,3]]}},"alternative-id":["10.1080\/14737140.2025.2501744"],"URL":"https:\/\/doi.org\/10.1080\/14737140.2025.2501744","relation":{},"ISSN":["1473-7140","1744-8328"],"issn-type":[{"value":"1473-7140","type":"print"},{"value":"1744-8328","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,8]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-01-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}